Benign prostatic hypertrophy (BPH)
Also known as: Benign prostatic hypertrophy, Prostate, Prostatic, Thickened, Thickening
Methodology & AI Transparency ⓘ
Benign prostatic hypertrophy (BPH) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Benign prostatic hypertrophy (BPH) (also termed Benign prostatic hypertrophy or Prostate) (N40.0; Prostate (BPH), Bladder & Urinary Tract) utilize hydration citrate protocols [Benign prostatic hypertrophy (BPH) N40.0] and objective IPSS Urinary Symptom in Benign prostatic hypertrophy (BPH) (N40.0: Score) targets (0 – 7 (mild symptoms) (N40.0)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Mapped to Prostate (BPH), Bladder & Urinary Tract under ICD-10-CM N40.0 for Benign prostatic hypertrophy (BPH) clinical workups.
- 3 Typical cash cost range: Workup highlights for Benign prostatic hypertrophy (BPH) (N40.0): hydration citrate protocols [Benign prostatic hypertrophy (BPH) N40.0].
- 4 Top reported side effects / signs: Follow-up benchmark in Benign prostatic hypertrophy (BPH): maintaining IPSS Urinary Symptom in Benign prostatic hypertrophy (BPH) (N40.0: Score) within 0 – 7 (mild symptoms) (N40.0).
Ask our AI Specialists anything about Benign prostatic hypertrophy (BPH)
What Is Benign prostatic hypertrophy (BPH)?
Physicians managing Benign prostatic hypertrophy (BPH) (also termed Benign prostatic hypertrophy or Prostate) (N40.0; Prostate (BPH), Bladder & Urinary Tract) utilize hydration citrate protocols [Benign prostatic hypertrophy (BPH) N40.0] and objective IPSS Urinary Symptom in Benign prostatic hypertrophy (BPH) (N40.0: Score) targets (0 – 7 (mild symptoms) (N40.0)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Benign prostatic hypertrophy (BPH) (code N40.0) is prostatic fibromuscular stromal in Benign prostatic hypertrophy (BPH) (N40.0: hyperplasia), which Prostate (BPH), Bladder & Urinary Tract clinicians address while surveilling IPSS Urinary Symptom in Benign prostatic hypertrophy (BPH) (N40.0: Score) (0 – 7 (mild symptoms) (N40.0)).
Common Symptoms & Clinical Signs
- • Presentation of Benign prostatic hypertrophy (BPH) (N40.0): burning dysuria, suprapubic in Benign prostatic hypertrophy (BPH) (N40.0: discomfort, or cloudy/hematuric)
- • Secondary Benign prostatic hypertrophy (BPH) clinical sign: sudden severe flank-to-groin in Benign prostatic hypertrophy (BPH) (N40.0: colicky pain caused)
- • Symptom flares in Benign prostatic hypertrophy (BPH) correlating with IPSS Urinary Symptom in Benign prostatic hypertrophy (BPH) (N40.0: Score) deviation outside 0 – 7 (mild symptoms) (N40.0)
- • Functional urology & prostate impact requiring hydration citrate protocols [Benign prostatic hypertrophy (BPH) N40.0] evaluation (N40.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Benign prostatic hypertrophy (BPH) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N40.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Prostate (BPH), Bladder & Urinary Tract | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: IPSS Urinary Symptom in Benign prostatic hypertrophy (BPH) (N40.0: Score) | 0 – 7 (mild symptoms) (N40.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urinalysis & Post-Void in Benign prostatic hypertrophy (BPH) (N40.0: Residual (PVR)) | Negative leukocyte/nitrite; PVR < 50 mL (N40.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Total PSA & in Benign prostatic hypertrophy (BPH) (N40.0: Serum Creatinine/eGFR) | Age-specific PSA; eGFR > 75 mL/min (N40.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Benign prostatic hypertrophy (BPH)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Dutasteride and Tamsulosin Hydrochloride Jalyn • RxCUI 996097 | 5-alpha Reductase Inhibitor | 85% | $1.8643 | $ 84.00 /mo |
| Terazosin Hydrochloride Hytrin • RxCUI 260376 | alpha-Adrenergic Blocker | 78% | $0.1246 | $ 7.45 /mo |
| Glycine Glycine Generic • RxCUI 310571 | FDA Prescription Therapeutic Agent | 77% | $2.0400 | $ 91.12 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Benign prostatic hypertrophy (BPH))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction: What a 1,075-Participant Study Found Low TT levels at baseline did not negatively influence response to tadalafil in men of advancing age with concomitant lower urinary tract symptoms and benign prostatic hyperplasia and erectile dysfunction. The journal of sexual medicine • 2016-05-15 • Randomized Controlled Trial | N = 1,075 | 96/100 | PMID 27017071 ↗ |
| New Insights on Benefits and safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to: What a 1,144-Participant Study Found However, therapy discontinuation due to pain and AEs did not increase with increase in AEs. American journal of men's health • 2020-01-15 • Meta-Analysis | N = 1,144 | 94/100 | PMID 33342335 ↗ |
| New Insights on Monotherapies and Combination Therapy of Tamsulosin and Tadalafil for Treating: What a 1,531-Participant Study Found Tadalafil combined with tamsulosin was more effective in the treatment of male LUTS/BPH, with or without ED, on the improvement of total IPSS, QoL, and Qmax. Urologia internationalis • 2024-01-15 • Meta-Analysis | N = 1,531 | 94/100 | PMID 38081154 ↗ |
| New Insights on Tadalafil on nighttime voiding (nocturia) in men with lower urinary tract: What a 752-Participant Study Found A statistically significant improvement in nocturnal frequency was seen with tadalafil over placebo; however, the treatment difference was small and not considered clinically meaningful. World journal of urology • 2014-10-15 • Randomized Controlled Trial | N = 752 | 93/100 | PMID 24504761 ↗ |
| New Insights on Heart and blood vessel risk factors and related comorbid conditions and medical: What a 746-Participant Study Found Once-daily tadalafil 5 mg improved LUTS/BPH, regardless of severity, in men with coexisting heart and blood vessel risk factors/comorbidities, except for patients with history of > 1 drug for arterial high blood pressure. International journal of clinical practice • 2015-12-15 • Randomized Controlled Trial | N = 746 | 93/100 | PMID 26299520 ↗ |
Benign prostatic hypertrophy (BPH) Patient Community & “People Like Me” Threads
Filter Benign prostatic hypertrophy (BPH) community threads and patient logs by age, biological sex, dosage, and treatment duration.